Tenofovir Disoproxil Fumarate/Dolutegravir/Lamivudine

富马酸替诺福韦二吡呋酯/多替拉韦/拉米夫定

Report date: 2025/03/19 16:22:37

Base Information

Drug NameTenofovir Disoproxil Fumarate/Dolutegravir/Lamivudine

Drug Alias NameN/A

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues

Mechanisms of ActionReverse transcriptase inhibitorsHIV integrase inhibitorsHBV DNA Polymerase inhibitors

TargetsHIV integraseReverse transcriptaseHBV DNA Polymerase

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Africa

Global Highest StatusApproved

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsHIV Infections

Inactive IndicationsN/A

ATC CodeJ05AR27